The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
18-Jul-05
$101 million
Target:
TeleCity Plc
Acquiror:
Inhoco 3236 plc (joint venture between 3i and Oak Hill Capital)
Advised TeleCity plc on the recommended offer by 3i and Oak Hill Capital
09-Sep-05
$1.0 billion
Target:
7-Eleven, Inc.
Acquiror:
Seven-Eleven Japan Co., Ltd
Advised the special committee of 7-Eleven, Inc. in connection with its evaluation of an unsolicited tender offer commenced by Seven-Eleven Japan Co., Ltd
24-Mar-06
$21.2 billion
Target:
Schering AG
Acquiror:
Bayer AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
08-Aug-06
$565 million
Target:
Emdeon Practice Services, Inc.
Acquiror:
The Sage Group plc
Advised The Sage Group plc, a leading international supplier of accounting and business management software solutions
06-Nov-06
$4.2 billion
Target:
Kos Pharmaceuticals, Inc.
Acquiror:
Abbott Laboratories
Advised Kos Pharmaceuticals, Inc., a specialty pharmaceutical provider of cardiovascular and respiratory drugs, on its sale to Abbott Laboratories
18-Dec-06
$NA
Target:
InBev SA
Acquiror:
Mr. Wolfgang Dinkelacker
Advised InBev SA, the world's largest brewery, on the sale of German regional brewery Dinkelacker-Schwaben Bräu KG
19-Dec-06
$270 million
Target:
Brion Technologies, Inc.
Acquiror:
ASML Holding N.V.
Advised ASML Holding N.V., a leading provider of lithography systems for the semiconductor industry, on its acquisition of Brion Technologies, Inc.
25-Jan-07
$3.3 billion
Target:
Cardinal Health, Inc., Pharmaceutical Technologies and Services division
Acquiror:
The Blackstone Group
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries
30-Mar-07
$24.4 billion
Target:
Alliance Boots plc
Acquiror:
Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina
Advised Alliance Boots plc, the leading international pharmacy-led health and beauty group, on a proposal regarding an offer for the company from a consortium comprising of Kohlberg Kravis Roberts & Co. Ltd. and Stefano Pessina
16-Jul-07
$2.1 billion
Target:
Applebee’s International, Inc.
Acquiror:
IHOP Corp.
Sole advisor to IHOP Corp., the fastest growing family dining concept in the US, on its acquisition of Applebee's
22-Jan-08
$3.4 billion
Target:
Ventana Medical Systems, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
23-Apr-08
$2.8 billion
Target:
Wendy's International, Inc.
Acquiror:
Triarc Companies, Inc.
Advised the special committee of the board of directors in connection with its merger with Triarc Companies, Inc., the operator of the Arby’s franchise. The combined systems will have approximately 10,000 restaurant units and pro forma annual system sales of approximately $12.5 billion, positioning it as the nation’s third largest quick service restaurant company
12-Jun-08
$6.7 billion
Target:
Applied Biosystems Group
Acquiror:
Invitrogen Corporation
Provided fairness opinion to the Board of Directors of the Applera Corporation on the merger of its Applied Biosystems business, which serves the life science industry, with the Invitrogen Corporation, creating a global leader in biotechnology reagents and systems
05-Aug-08
$NA
Target:
BARTEC Group
Acquiror:
Capvis
Advised Capvis, a leading Swiss private equity firm, on its acquisition of the BARTEC Group, a leading European provider of industrial safety technology, from Allianz Capital Partners, the captive private equity arm of Allianz AG, and the Barlian family (founding family)
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
23-Mar-09
$NA
Target:
BearingPoint, Inc.
Acquiror:
Various
Advised BearingPoint, Inc. on the sale of substantially all of its assets, pursuant to a Section 363 process
23-Jun-09
$155 million
Target:
Monogram Biosciences, Inc.
Acquiror:
Laboratory Corporation of America Holdings
Advised LabCorp on the acquisition of Monogram Biosciences, a molecular diagnostics company focused on guiding and improving the treatment of serious infectious diseases and cancer
10-Aug-09
$596 million
Target:
Barnes & Noble College Booksellers, Inc.
Acquiror:
Barnes & Noble, Inc.
Advised the Special Committee of the Board of Directors of Barnes & Noble, Inc., the world’s largest bookseller, on its acquisition of Barnes & Noble College Booksellers, Inc.
06-Oct-09
$1.2 billion
Target:
Avocent Corporation
Acquiror:
Emerson Electric Co.
Advised Emerson Electric Co., a diversified global technology and industrial company, on its acquisition of Avocent Corporation, a manufacturer of software and hardware products
06-Oct-09
$263 milllion
Target:
ICT Group
Acquiror:
Sykes Enterprises
Advised ICT Group on its merger with Sykes Enterprises, both leading global providers of outsourced customer contact management solutions and services
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
04-Dec-09
$NA
Target:
Verivox Holding Limited
Acquiror:
Oakley Capital Private Equity LP
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
23-Feb-10
$NA
Target:
Heartscape Technologies, Inc.
Acquiror:
Roper Industries, Inc.
Advised Heartscape Technologies, a medical device company on its sale of substantially all its assets to Roper Industries, a diversified growth company
25-Feb-10
$14.4 billion
Target:
Coca-Cola Enterprises Inc.
Acquiror:
The Coca-Cola Company
Advised the Affiliated Transaction Committee of Coca-Cola Enterprises Inc. on the sale of its North American bottling operations to The Coca-Cola Company and on its concurrent acquisition of The Coca-Cola Company’s bottling operations in the Nordic region
05-Apr-10
$225 million
Target:
Medegen, Inc
Acquiror:
CareFusion Corporation
Advised Medegen, Inc., a medical device company that develops, manufactures and markets clinically superior disposable intravenous therapy products on its sale to CareFusion, a global medical devices company